Neurol. praxi. 2009;10(1):19-23

Mannitol, hypertonic saline and corticoids in the treatment of intracranial hypertension

MUDr. Denisa Vondráčková
Neurologické oddělení Nemocnice Na Homolce, Praha

Every neurologist is familiar with usage of osmotically active substances and glucocorticoids in the treatment of intracranial hypertension

– these medicaments were introduced into clinical practice more than 50 years ago and the abundant literature supporting their role

in this indication is convincing. Bearing this in mind, it is even more interesting that we still don’t know the precise mechanism of their

action and there is no consensus regarding the ideal dosage of osmotically active substances, timing of treatment and their effectiveness

in different indications. Established treatment algorithms are, however, universally accepted and practiced. We briefly summarize the

current state of knowledge and practical approach to the management of intracranial hypertension using the above substances and we

also point to certain widely accepted fictions that probably lack any rational background.

Keywords: mannitol, hypertonic saline, corticoids, intracranial hypertension.

Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vondráčková D. Mannitol, hypertonic saline and corticoids in the treatment of intracranial hypertension. Neurol. praxi. 2009;10(1):19-23.
Download citation

References

  1. Alderson P, Roberts I. Corticosteroids for acute traumatic brain injury. Cochrane Database of Systematic Reviews 2004; 4: CD000196. Go to original source... Go to PubMed...
  2. Anderson DC, Cranford RE. Glucocorticoids in ischemic stroke. Stroke 1979; 10: 68-71. Go to original source... Go to PubMed...
  3. Diringer MN, Zazulia AR. Osmotic Therapy: Fact and Fiction. Neurocrit Care. 2004; 1(2): 219-233. Go to original source... Go to PubMed...
  4. Francony G, Fauvage B, Falcon D, et al. Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Crit Care Med 2008; 36: 795-800. Go to original source... Go to PubMed...
  5. Galicich JH, French LA, Melby JC. Use of dexametasone in treatment of cerebral edema associated with brain tumor. J Lancet 1961; 31: 46-53.
  6. García-Morales EJ, Cariappa R, Parvin CA, et al. Osmole gap in neurologic-neurosurgical intensive care unit: Its normal value, calculation, and relationship with mannitol serum concentrations. Crit Care Med 2004; 32: 986-991. Go to original source... Go to PubMed...
  7. Gomes JA, Stevens RD, Lewin III JJ, et al. Glucocorticoid therapy in neurologic critical care. Crit Care Med 2005; 33: 1214-1224. Go to original source... Go to PubMed...
  8. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee. Cerebrovasc Dis 2008; 25: 457-507. Go to original source... Go to PubMed...
  9. Katzman R, Clasen R, Klatzo I, et al. Brain edema in stroke. Stroke 1977; 8: 512-540. Go to original source... Go to PubMed...
  10. Leskot T, Abdennour L, Boch AL, et al. Treatment of intracranial hypertension. Curr Opin Crit Care 2008, 14: 129-134. Go to original source... Go to PubMed...
  11. Lüllmann H, Mohr K, Wehling M. Farmakologie a toxikologie. Grada Publising, 2004; 438-444.
  12. Paleologos N, Vick NA. Corticosteroids in Neuro-Oncology. In: Cancer Neurology in Clinical Practice 2004. Humana Press Inc. Totowa NJ.
  13. Parrillo JE, Dellinger RP. Critical Care Medicine - Principles of diagnosis and management in the adult. Third edition. Mosby Elsevier, Philadelphia 2008; 1409-1410.
  14. Ropper AH. Neurological and neurosurgical intensive Care, 4 th ed., Lippincott Williams & Wilkins, 2004; 40-43, 247-249.
  15. Sinha S, Bastin ME, Wardlaw JM, et al. Effects of dexametasone on peritumoral oedematous brain: A DT-MRI study. J Neurol Neurosurg Psychiatry 2004; 75: 1632-1635. Go to original source... Go to PubMed...
  16. Soffietti R, Ruda R, Mutani R. Management of brain metastase. J Neurol 2002; 249: 357-1369. Go to original source... Go to PubMed...
  17. Špatenková V, Kazda A. Osmolality changes during mannitol therapy in cerebral oedema. Critical Care 2003; 7(Suppl 2): P 077. Go to original source...
  18. Thambisetty M, Lavin PJ, Newman NJ, et al. Fulminant idiopathic intracranial hypertension. Neurology 2007; 68: 229-232. Go to original source... Go to PubMed...
  19. Wakai A, Roberts I, Schierhout G. Mannitol for acute traumatic brain injury. Cochrane Database Syst Rev 2007; CD001049. Go to original source...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.